Nuo Therapeutics, Inc.

Equities

AURX

US67059V2097

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 08:02:22 10/06/2024 pm IST			5-day change	1st Jan Change
0.9 ^USD	+20.00%		+20.00%	+63.64%

20/05	Nuo Therapeutics, Inc. announced that it has received $0.650875 million in funding	CI
15/05	Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

May 21, 2019 at 02:32 am IST

Nuo Therapeutics, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced total revenue was USD 39,229 compared to USD 159,943 a year ago. Operating loss was USD 611,833 compared to USD 667,726 a year ago. Net loss was USD 679,909 compared to USD 670,247 a year ago. Basic loss per share was USD 0.03 compared to USD 0.03 a year ago.

Latest news about Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. announced that it has received $0.650875 million in funding	20/05	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.650875 million in funding	10/05	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/04	CI
Exor-backed NUO invests in Italian teenage clothing chain Subdued	19/03	RE
Nuo Therapeutics, Inc. announced that it has received $0.9625 million in funding	19/12	CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.9625 million in funding	08/12	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Insider Buy: Nuo Therapeutics	04/23/04	MT
Nuo Therapeutics, Inc. announced that it has received $1.035 million in funding	01/23/01	CI
Nuo Therapeutics, Inc. announced that it expects to receive $1.035 million in funding	26/23/26	CI
Nuo Therapeutics Selects to Exhibit AurixÂ® System At Vizient Innovative Technology Exchange	27/23/27	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17	CI
Nuo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	17/23/17	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	05/22/05	CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.5 million in funding from Pacific Medical, Inc.	24/22/24	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/22/09	CI
Nuo Therapeutics, Inc. Enters into an Exclusive Sales Agent and Services Agreement with Pacific Medical, Inc	28/22/28	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	17/22/17	CI
Insider Buy: Nuo Therapeutics	03/22/03	MT
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	16/22/16	CI
Nuo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	15/22/15	CI
Nuo Therapeutics, Inc. announced that it expects to receive $3.55 million in funding	11/22/11	CI

Chart Nuo Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. Its commercial offering consists of point of care technology for the separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix or the Aurix System. The Aurix System produces a platelet rich plasma (PRP) gel at the point of care using the patient's own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NUO THERAPEUTICS, INC.	+63.64%	33.83M
VERTEX PHARMACEUTICALS INCORPORATED	+18.19%	125B
REGENERON PHARMACEUTICALS, INC.	+13.49%	108B
BIONTECH SE	-7.13%	24.21B
ARGENX SE	+2.07%	22.78B
GENMAB A/S	-10.79%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.51%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+1.13%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.77%	11.66B

Bio Therapeutic Drugs